Educate About Nirsevimab to Prevent RSV
October 2023
You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.
RSV is the most common cause of hospitalization in U.S. infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.
Nirsevimab is a monoclonal antibody given IM in the clinic or hospital...similar to palivizumab (Synagis). You’ll hear some people call nirsevimab a vaccine...since it’s a form of passive immunization.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote